Global Strategic Partnerships
Charles River is prioritizing innovation in science and technology to enhance the way we serve our clients and bring novel therapies to patients safely and swiftly through partnerships and collaborations across key focus areas.
Alternatives to In Vivo Models
PathoQuest*
We’ve expanded our comprehensive portfolio of services to include next-generation sequencing (NGS) services, powerful alternative to animal testing and compliance assistance in the detection of viral contaminants in Biologics, through this partnership. *Partnership to acquisition.
Retrogenix®*
Rounding out our large molecule and cell therapy capabilities, the proprietary Retrogenix® Cell Microarray Technology uncovers high quality, exploitable drug targets and mechanisms of action as well as screens for potential off-targets to inform lead selection and generates high quality IND-enabling specificity data. *Partnership to acquisition.
Toxys ReproTracker®
Through our partnership with Toxys, Charles River clients gain streamlined access to ReproTracker®—a human stem cell-based in vitro assay that complements traditional DART methods. It enables early-phase developmental toxicity screening, animal-free teratogenicity testing, and extrapolation of animal data to humans.
Digital Technologies
Deciphex
Through our partnership with Deciphex, we accelerate pathology assessments using advanced digital pathology tools for faster, more efficient data delivery. In parallel, our VICT3R initiative pioneers Virtual Control Groups to reduce animal use in toxicology research, enhancing scientific rigor and supporting ethical practices aligned with the 3Rs.
Fios Genomics
Our longstanding relationship with Fios Genomics gives clients access to bioinformatics data analysis services, including expert analytical support for the microarrays, next generation sequencing (NGS), proteomics, metabolomics, epigenetics, and associated metadata that keeps their projects moving forward.
RockStep
In our pursuit to digitize our in vivo research, we transitioned from our homegrown, purpose-built in vivo software to a best-of-breed tech model to realize our vision of the lab of the future. With RockStep Solutions’ Climb™, we can manage and streamline in vivo study workflows, efficiently collaborate, and ensure robust high-quality study data.
Biologic Modalities
Wheeler Bio
Charles River’s strategic agreement with Wheeler Bio aims to support clients through their antibody development. Our experience in antibody discovery services, safety, and analytics, coupled with Wheeler’s Portable CMC® platform, helps accelerate therapeutic discovery to IND submission timelines.
Enabling Platforms
aTEM Structural Discovery
This strategic partnership provides access to aTEM’s cryo electron microscopy (cryo-EM) service solutions that determine the 3D structures of proteins. The combination of ATEM’s cryo-EM expertise with our structural biology capabilities has the potential to accelerate discovery efforts from hit design through lead optimization.
We are leading the industry into the next frontier of drug discovery and development through collaborations that allow us to deliver on alternatives to animal models in research.
Explore our NAM Partnerships
Explore our Discovery Partnerships